Metformin + Intermittent Insulin Therapy — Competitive Intelligence Brief

Metformin + Intermittent Insulin Therapy (Metformin + Intermittent Insulin Therapy) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination therapy. Area: Diabetes.

phase 3 Antidiabetic combination therapy Diabetes Small molecule

Target snapshot

Metformin + Intermittent Insulin Therapy (Metformin + Intermittent Insulin Therapy) — Mount Sinai Hospital, Canada. Metformin reduces hepatic glucose production and improves insulin sensitivity, while intermittent insulin therapy provides periodic exogenous insulin to maintain glycemic control.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin + Intermittent Insulin Therapy TARGET	Metformin + Intermittent Insulin Therapy	Mount Sinai Hospital, Canada	phase 3	Antidiabetic combination therapy
Metformin + Insulin	Metformin + Insulin	University of Virginia	marketed	Antidiabetic combination therapy	AMPK (metformin); Insulin receptor (insulin)
Biguanides, thiazolidinediones	Biguanides, thiazolidinediones	University of Pittsburgh	phase 3	Antidiabetic combination therapy	PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component)
Metformin, glyburide and insulin	Metformin, glyburide and insulin	Université de Sherbrooke	phase 3	Antidiabetic combination therapy (biguanide + sulfonylurea + insulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination therapy class)

1. Mount Sinai Hospital, Canada · 1 drug in this class
2. University of Pittsburgh · 1 drug in this class
3. University of Virginia · 1 drug in this class